poisar

Stocks · News reference

Cantor Fitzgerald Initiates Coverage On Ensysce Biosciences with Overweight Rating, Announces Price Target of $2

BenzingaBenzinga Newsdesk

Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Overweight rating and announces Price Target of $2.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Fiscal.ai

    Ensysce Biosciences Announces CEO Transition

    Ensysce Biosciences announced that CEO Lynn Kirkpatrick will transition to the role of Chief Operating Officer, with President James Morrisson set to assume the CEO position following the company's annual meeting on December 14, 2026.